Double-blind randomised trial of saline solution for gargling and nasal rinsing in SARS-CoV-2 infection.

Publication date: Dec 30, 2024

Previous studies have shown that hypertonic saline nasal irrigation and gargling reduced the duration of symptoms in upper respiratory infections caused by coronavirus. This study aims to investigate the effects of two saline regimens on symptoms associated with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Between 2020 and 2022, individuals aged 18-65 years who tested positive for SARS-CoV-2 infection via polymerase chain reaction (PCR) were randomly assigned to either low- or high-saline regimens for 14 days. The low-saline solutions contained 2. 13 g of salt dissolved in eight ounces of warm water, while the high-saline solution contained six grams of salt dissolved in eight ounces of warm water. Participants gargled and rinsed their nasal passages four times a day for 14 days. Primary outcomes assessed included frequency and duration of SARS-CoV-2 symptoms, while secondary outcomes included hospital or intensive care unit (ICU) admission, need for mechanical ventilatory support, or mortality rates. Exclusion criteria included chronic hypertension or participation in other interventional studies. Fifty-eight individuals were allocated to the low (n = 27) or high (n = 28) saline regimens; with three lost to follow-up. There were no significant differences in primary or secondary outcomes between these groups. Comparatively, during the study period, 9398 individuals with confirmed SARS-CoV-2 infection by positive PCR test were observed as a reference group. Hospitalisation rates in the low-saline (18. 5%) and high-saline (21. 4%) regimens were significantly lower than in the reference group (58. 8%; P 

Open Access PDF

Concepts Keywords
Coronavirus Adolescent
Grams Adult
Hypertension Aged
Rinsed COVID-19
Double-Blind Method
Female
Humans
Male
Middle Aged
Nasal Lavage
Saline Solution
Saline Solution
SARS-CoV-2
Treatment Outcome
Young Adult

Semantics

Type Source Name
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease MESH upper respiratory infections
drug DRUGBANK Water
disease MESH hypertension
disease MESH lost to follow-up
disease IDO intervention
drug DRUGBANK Coenzyme M
disease MESH severe acute respiratory syndrome
disease MESH emergency
disease IDO replication
disease MESH influenza
disease MESH parainfluenza
disease MESH infections
disease MESH viral load
disease IDO symptom
disease MESH virus infection
disease IDO assay
drug DRUGBANK Azithromycin
drug DRUGBANK Hydroxychloroquine
disease IDO infection
disease MESH chronic renal disease
disease MESH complications
disease MESH pneumonia
disease IDO facility

Original Article

(Visited 1 times, 1 visits today)